RxDoctor Payments Data

John Getsos, MD

Internal Medicine · New York, NYNPI 1104049030

Payments from drug & device makers

$3,055in general payments, 2019–2025

Across 143 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$456
  • Pfizer$404
  • Novo Nordisk$346
  • Idorsia Pharmaceuticals US Inc$309
  • Bausch Health US, LLC$285
  • Lilly USA, LLC$260
  • plus $995 from 11 others

What the payments were for

  • Food & beverage$3,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,055 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$133,950
Medicare patients
398
Services billed
2,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$122,497
JardianceEmpagliflozin51$77,526
OzempicSemaglutide28$53,312
XareltoRivaroxaban23$31,341
UbrelvyUbrogepant14$30,609
Nurtec OdtRimegepant Sulfate12$27,336
JanumetSitagliptin Phos/Metformin Hcl25$24,681
EntrestoSacubitril/Valsartan12$22,540
RybelsusSemaglutide22$20,940
CreonLipase/Protease/Amylase14$19,865
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,119
Repatha SureclickEvolocumab17$8,759
Emgality PenGalcanezumab-Gnlm13$8,686
LinzessLinaclotide11$6,168
Atorvastatin Calcium557$5,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$404$149,833118 claims
Novo NordiskOzempic, Rybelsus$346$74,25250 claims
AbbVieUbrelvy, Creon, Linzess, Synthroid$456$60,981102 claims
Johnson & JohnsonXarelto$171$31,34123 claims
GSKTrelegy Ellipta$217$14,11915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →